ReviewCancer imaging : the official publication of the International Cancer Imaging Society2010
Whole-body diffusion-weighted imaging in lymphoma.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- Whole-body diffusion-weighted imaging with background body signal suppression and quantitative apparent diffusion coefficient in the detection, staging, and grading of non-Hodgkin lymphoma.Polish journal of radiology · 2023Article
- Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Whole-body [EJNMMI research · 2021Article
- Beyond adenocarcinoma: MRI of uncommon rectal neoplasms and mimickers.Abdominal radiology (New York) · 2019Review
- Feasibility of diffusion-weighted imaging with DWIBS in staging Hodgkin lymphoma in pediatric patients: comparison with PET/CT.Magma (New York, N.Y.) · 2019Article
- Application of the apparent diffusion coefficient in magnetic resonance imaging in an assessment of the early response to treatment in Hodgkin's and non-Hodgkin's lymphoma - pilot study.Polish journal of radiology · 2018Article
- Whole-body MRI in patients with lymphoma: collateral findings.La Radiologia medica · 2016Article
- Uncommon liver tumors: Case report and literature review.Medicine · 2016Review
- Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and (18)F-FDG-PET/CT.Gastroenterology research and practice · 2015Article
- Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.American journal of nuclear medicine and molecular imaging · 2015Article
- Influence of selected b values on ADC quantification in diffusion-weighted MRI. Comment on Punwani et al.: Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI?European journal of nuclear medicine and molecular imaging · 2013Article
- PET/MRI in cancer patients: first experiences and vision from Copenhagen.Magma (New York, N.Y.) · 2013Article
- Article
- Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2012Article
- Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review.Skeletal radiology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current evidence regarding the usefulness of whole-body diffusion-weighted magnetic resonance imaging (DWI) in lymphoma is reviewed. DWI is capable of combining anatomical and functional information and is becoming a valuable tool in oncology, in particular for staging purposes. DWI may prove to be a useful biomarker in clinical decision making for patients with lymphoma. Large-scaled prospective studies are needed to confirm these preliminary results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.